Dramatic decline in substance use by HIV-infected pregnant women in the United States from 1990 to 2012

Kathryn Rough, Katherine Tassiopoulos, Deborah Kacanek, Raymond Griner, Ram Yogev, Kenneth C Rich, George R Seage 3rd, Pediatric HIVAIDS Cohort Study, William Shearer, Mary Paul, Norma Cooper, Lynette Harris, Murli Purswani, Emma Stuard, Anna Cintron, Ana Puga, Dia Cooley, Doyle Patton, Deyana Leon, Ram Yogev, Margaret Ann Sanders, Kathleen Malee, Scott Hunter, William Borkowsky, Sandra Deygoo, Helen Rozelman, Katherine Knapp, Kim Allison, Midnela Acevedo-Flores, Lourdes Angeli-Nieves, Vivian Olivera, Hermann Mendez, Ava Dennie, Susan Bewley, Russell Van Dyke, Karen Craig, Patricia Sirois, Marilyn Crain, Newana Beatty, Dan Marullo, Stephen Spector, Jean Manning, Sharon Nichols, Elizabeth McFarland, Emily Barr, Robin McEvoy, Mobeen Rathore, Kristi Stowers, Ann Usitalo, Kenneth Rich, Lourdes Richardson, Delmyra Turpin, Renee Smith, Arry Dieudonne, Linda Bettica, Susan Adubato, Gwendolyn Scott, Claudia Florez, Elizabeth Willen, Toinette Frederick, Mariam Davtyan, Maribel Mejia, Zoe Rodriguez, Ibet Heyer, Nydia Scalley Trifilio, Kathryn Rough, Katherine Tassiopoulos, Deborah Kacanek, Raymond Griner, Ram Yogev, Kenneth C Rich, George R Seage 3rd, Pediatric HIVAIDS Cohort Study, William Shearer, Mary Paul, Norma Cooper, Lynette Harris, Murli Purswani, Emma Stuard, Anna Cintron, Ana Puga, Dia Cooley, Doyle Patton, Deyana Leon, Ram Yogev, Margaret Ann Sanders, Kathleen Malee, Scott Hunter, William Borkowsky, Sandra Deygoo, Helen Rozelman, Katherine Knapp, Kim Allison, Midnela Acevedo-Flores, Lourdes Angeli-Nieves, Vivian Olivera, Hermann Mendez, Ava Dennie, Susan Bewley, Russell Van Dyke, Karen Craig, Patricia Sirois, Marilyn Crain, Newana Beatty, Dan Marullo, Stephen Spector, Jean Manning, Sharon Nichols, Elizabeth McFarland, Emily Barr, Robin McEvoy, Mobeen Rathore, Kristi Stowers, Ann Usitalo, Kenneth Rich, Lourdes Richardson, Delmyra Turpin, Renee Smith, Arry Dieudonne, Linda Bettica, Susan Adubato, Gwendolyn Scott, Claudia Florez, Elizabeth Willen, Toinette Frederick, Mariam Davtyan, Maribel Mejia, Zoe Rodriguez, Ibet Heyer, Nydia Scalley Trifilio

Abstract

Objective: We aimed to describe temporal changes in substance use among HIV-infected pregnant women in the United States from 1990 to 2012.

Design: Data came from two prospective cohort studies (Women and Infants Transmission Study and Surveillance Monitoring for Antiretroviral Therapy Toxicities Study).

Methods: Women were classified as using a substance during pregnancy if they self-reported use or had a positive biological sample. To account for correlation between repeated pregnancies by the same woman, generalized estimating equation models were used to test for temporal trends and evaluate predictors of substance use.

Results: Over the 23-year period, substance use among the 5451 HIV-infected pregnant women sharply declined; 82% of women reported substance use during pregnancy in 1990, compared with 23% in 2012. Use of each substance decreased significantly (P < 0.001 for each substance) in an approximately linear fashion, until reaching a plateau in 2006. Multivariable models showed substance use was inversely associated with receiving antiretroviral therapy. Among the subset of 824 women with multiple pregnancies under observation, women who used a substance in their previous pregnancy were at elevated risk of substance use during their next pregnancy (risk ratio, 5.71; 95% confidence interval, 4.63-7.05).

Conclusion: A substantial decrease in substance use during pregnancy was observed between 1990 and 2012 in two large US cohorts of HIV-infected women. Substance use prevalence in these cohorts became similar to that of pregnant women in the general US population by the mid-2000s, suggesting that the observed decrease may be due to an epidemiological transition of the HIV epidemic among women in the United States.

Conflict of interest statement

Conflicts of Interest: All authors declare that they have no conflicts of interest related to this manuscript.

Figures

Figure 1
Figure 1
Proportion of HIV-Infected Women Using Substances during Pregnancy, by Delivery Year (N = 5,451)

References

    1. Taylor AW, Little KM, Zhang X, Borkowf CB, Whitmore SK, Weidle PJ, et al. Estimated perinatal antiretroviral exposures, cases prevented and infected infants in the era of antiretroviral prophylaxis in the United States. 19th Conference on Retroviruses and Opportunistic Infections; Seattle, WA. 2012.
    1. Whitmore SK, Zhang X, Taylor AW, Blair JM. Estimated number of infants born to HIV-infected women in the United States and five dependent areas, 2006. J Acquir Immune Defic Syndr. 2011;57:218–222.
    1. Nair P, Alger L, Hines S, Seiden S, Hebel R, Johnson JP. Maternal and neonatal characteristics associated with HIV infection in infants of seropositive women. J Acquir Immune Defic Syndr. 1993;6:298–302.
    1. Rodriguez EM, Mendez H, Rich K, Sheon A, Fox H, Green K, et al. Maternal drug use in perinatal HIV studies. The Women and Infants Transmission Study. Ann N Y Acad Sci. 1993;693:245–248.
    1. Landesman SH, Kalish LA, Burns DN, Minkoff H, Fox HE, Zorrilla C, et al. Obstetrical factors and the transmission of human immunodeficiency virus type 1 from mother to child. The Women and Infants Transmission Study. N Engl J Med. 1996;334:1617–1623.
    1. Purohit V, Rapaka RS, Schnur P, Shurtleff D. Potential impact of drugs of abuse on mother-to-child transmission (MTCT) of HIV in the era of highly active antiretroviral therapy (HAART) Life Sci. 2011;88:909–916.
    1. Rodriguez EM, Mofenson LM, Chang BH, Rich KC, Fowler MG, Smeriglio V, et al. Association of maternal drug use during pregnancy with maternal HIV culture positivity and perinatal HIV transmission. AIDS. 1996;10:273–282.
    1. Whitmore SK, Taylor AW, Espinoza L, Shouse RL, Lampe MA, Nesheim S. Correlates of mother-to-child transmission of HIV in the United States and Puerto Rico. Pediatrics. 2012;129:e74–e81.
    1. Bateman DA, Ng SK, Hansen CA, Heagarty MC. The effects of intrauterine cocaine exposure in newborns. Am J Public Health. 1993;83:190–193.
    1. Day NL, Richardson GA, Geva D, Robles N. Alcohol, marijuana, and tobacco: effects of prenatal exposure on offspring growth and morphology at age six. Alcohol Clin Exp Res. 1994;18:786–794.
    1. Day NL, Richardson GA, Goldschmidt L, Robles N, Taylor PM, Stoffer DS, et al. Effect of prenatal marijuana exposure on the cognitive development of offspring at age three. Neurotoxicol Teratol. 1994;16:169–175.
    1. Goldschmidt L, Richardson GA, Willford J, Day NL. Prenatal marijuana exposure and intelligence test performance at age 6. J Am Acad Child Adolesc Psychiatry. 2008;47:254–263.
    1. Levine TP, Liu J, Das A, Lester B, Lagasse L, Shankaran S, et al. Effects of prenatal cocaine exposure on special education in school-aged children. Pediatrics. 2008;122:e83–e91.
    1. Lightwood JM, Phibbs CS, Glantz SA. Short-term health and economic benefits of smoking cessation: low birth weight. Pediatrics. 1999;104:1312–1320.
    1. Richardson GA, Goldschmidt L, Larkby C. Effects of prenatal cocaine exposure on growth: a longitudinal analysis. Pediatrics. 2007;120:e1017–e1027.
    1. Riley EP, McGee CL. Fetal alcohol spectrum disorders: an overview with emphasis on changes in brain and behavior. Exp Biol Med. 2005;230:357–365.
    1. Sexton M, Fox NL, Hebel JR. Prenatal exposure to tobacco: II. Effects on cognitive functioning at age three. Int J Epidemiol. 1990;19:72–77.
    1. Stroud LR, Paster RL, Goodwin MS, Shenassa E, Buka S, Niaura R, et al. Maternal smoking during pregnancy and neonatal behavior: a large-scale community study. Pediatrics. 2009;123:e842–e848.
    1. Zuckerman B, Frank DA, Hingson R, Amaro H, Levenson SM, Kayne H, et al. Effects of maternal marijuana and cocaine use on fetal growth. N Engl J Med. 1989;320:762–768.
    1. Katz IT, Shapiro R, Li D, Govindarajulu U, Thompson B, Watts DH, et al. Risk factors for detectable HIV-1 RNA at delivery among women receiving highly active antiretroviral therapy in the Women and Infants Transmission Study. J Acquir Immune Defic Syndr. 2010;54:27–34.
    1. Centers for Disease Control and Prevention. HIV/AIDS Surveillance Report, 1990. 1991
    1. Centers for Disease Control and Prevention. HIV Surveillance Report, 2011. 2013
    1. Sheon AR, Fox HE, Rich KC, Stratton P, Diaz C, Tuomala R, et al. The Women and Infants Transmission Study (WITS) of maternal-infant HIV transmission: study design, methods, and baseline data. J Womens Health. 1996;5:69–78.
    1. Williams PL, Seage GR, 3rd, Van Dyke RB, Siberry GK, Griner R, Tassiopoulos K, et al. A trigger-based design for evaluating the safety of in utero antiretroviral exposure in uninfected children of human immunodeficiency virus-infected mothers. Am J Epidemiol. 2012;175:950–961.
    1. Tassiopoulos K, Read JS, Brogly S, Rich K, Lester B, Spector SA, et al. Substance use in HIV-infected women during pregnancy: self-report versus meconium analysis. AIDS Behav. 2010;14:1269–1278.
    1. Substance Abuse and Mental Health Services Administration. Results from the 1994 National Survey on Drug Use and Health: national findings. Rockville, MD: Office of Applied Studies; 1995.
    1. Substance Abuse and Mental Health Services Administration. Results from the 1995 National Survey on Drug Use and Health: national findings. Rockville, MD: Office of Applied Studies; 1996.
    1. Substance Abuse and Mental Health Services Administration. Results from the 1996 National Survey on Drug Use and Health: national findings. Rockville, MD: Office of Applied Studies; 1997.
    1. Substance Abuse and Mental Health Services Administration. Results from the 1997 National Survey on Drug Use and Health: national findings. Rockville, MD: Office of Applied Studies; 1998.
    1. Substance Abuse and Mental Health Services Administration. Results from the 1998 National Survey on Drug Use and Health: national findings. Rockville, MD: Office of Applied Studies; 1999.
    1. Substance Abuse and Mental Health Services Administration. Results from the 1999 National Survey on Drug Use and Health: national findings. Rockville, MD: Office of Applied Studies; 2000.
    1. Substance Abuse and Mental Health Services Administration. Results from the 2000 National Survey on Drug Use and Health: national findings. Rockville, MD: Office of Applied Studies; 2001.
    1. Substance Abuse and Mental Health Services Administration. Results from the 2001 National Survey on Drug Use and Health: national findings. Rockville, MD: Office of Applied Studies; 2002.
    1. Substance Abuse and Mental Health Services Administration. Results from the 2002 National Survey on Drug Use and Health: national findings. Rockville, MD: Office of Applied Studies; 2003.
    1. Substance Abuse and Mental Health Services Administration. Results from the 2003 National Survey on Drug Use and Health: national findings. Rockville, MD: Office of Applied Studies; 2004.
    1. Substance Abuse and Mental Health Services Administration. Results from the 2004 National Survey on Drug Use and Health: national findings. Rockville, MD: Office of Applied Studies; 2005.
    1. Substance Abuse and Mental Health Services Administration. Results from the 2005 National Survey on Drug Use and Health: national findings. Rockville, MD: Office of Applied Studies; 2006.
    1. Substance Abuse and Mental Health Services Administration. Results from the 2006 National Survey on Drug Use and Health: national findings. Rockville, MD: Office of Applied Studies; 2007.
    1. Substance Abuse and Mental Health Services Administration. Results from the 2007 National Survey on Drug Use and Health: national findings. Rockville, MD: Office of Applied Studies; 2008.
    1. Substance Abuse and Mental Health Services Administration. Results from the 2008 National Survey on Drug Use and Health: national findings. Rockville, MD: Office of Applied Studies; 2009.
    1. Substance Abuse and Mental Health Services Administration. Results from the 2009 National Survey on Drug Use and Health: national findings. Rockville, MD: Office of Applied Studies; 2010.
    1. Substance Abuse and Mental Health Services Administration. Results from the 2010 National Survey on Drug Use and Health: national findings. Rockville, MD: Office of Applied Studies; 2011.
    1. Substance Abuse and Mental Health Services Administration. Results from the 2011 National Survey on Drug Use and Health: national findings. Rockville, MD: Office of Applied Studies; 2012.
    1. Substance Abuse and Mental Health Services Administration. Results from the 2012 National Survey on Drug Use and Health: national findings. Rockville, MD: Office of Applied Studies; 2013.
    1. Sohler NL, Wong MD, Cunningham WE, Cabral H, Drainoni ML, Cunningham CO. Type and pattern of illicit drug use and access to health care services for HIV-infected people. AIDS Patient Care STDS. 2007;21(Suppl 1):S68–S76.
    1. Celentano DD, Vlahov D, Cohn S, Shadle VM, Obasanjo O, Moore RD. Self-reported antiretroviral therapy in injection drug users. JAMA. 1998;280:544–546.
    1. Strathdee SA, Palepu A, Cornelisse PG, Yip B, O'Shaughnessy MV, Montaner JS, et al. Barriers to use of free antiretroviral therapy in injection drug users. JAMA. 1998;280:547–549.
    1. Halstead AC, Godolphin W, Lockitch G, Segal S. Timing of specimen collection is crucial in urine screening of drug dependent mothers and newborns. Clin Biochem. 1988;21:59–61.
    1. Ostrea EM, Brady M, Gause S, Raymundo AL, Stevens M. Drug screening of newborns by meconium analysis: a large-scale, prospective, epidemiologic study. Pediatrics. 1992;89:107–113.
    1. Ostrea EM, Jr, Knapp DK, Tannenbaum L, Ostrea AR, Romero A, Salari V, et al. Estimates of illicit drug use during pregnancy by maternal interview, hair analysis, and meconium analysis. J Pediatr. 2001;138:344–348.

Source: PubMed

Patrocinadores y Colaboradores

Condiciones médicas

Intervenciones de drogas

3
Suscribir